{"id":"CHEMBL100014","canonicalSmiles":"CCCC(=O)OCOC(=O)C(C)(C)C","inchiKey":"GYKLFBYWXZYSOW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AN-9","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["An-9","Butyric Acid 2,2-Dimethyl-Propionyloxymethyl Ester","Butyric Acid 2,2-Dimethyl-Propionyloxymethyl Ester(An9)","Pivanex"],"crossReferences":{"drugbank":["DB05103"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL10188","canonicalSmiles":"CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1","inchiKey":"BIAVGWDGIJKWRM-FQEVSTJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TALNETANT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SB-2234","SB-223412","Sb-223412","Talnetant"],"childChemblIds":["CHEMBL2146089"],"linkedTargets":{"rows":["ENSG00000169836"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000555"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1051","canonicalSmiles":"CC(C)OC(=O)CCC/C=C\\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1","inchiKey":"GGXICVAJURFBLW-CEYXHVGTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LATANOPROST","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Latanoprost","Monopost","Xalatan","Xelpros"],"synonyms":["Latanoprost","Latanoprost (isopropyl ester)","PHXA-41","PHXA41","T-2345","T2345","XA-41","XA41"],"crossReferences":{"DailyMed":["latanoprost"],"PubChem":["26719861"],"Wikipedia":["Latanoprost"],"drugbank":["DB00654"],"chEBI":["6384"]},"linkedTargets":{"rows":["ENSG00000122420"],"count":1},"linkedDiseases":{"rows":["EFO_0006862","EFO_0004190","EFO_1001069","EFO_0004192","EFO_1000906","EFO_0003770","EFO_0004208","EFO_0000516","EFO_0000537"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL1088750","canonicalSmiles":"CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(C(=O)NCCN(C)C)cc21","inchiKey":"IFGWYHGYNVGVRB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARRY-797","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ARRY-371797","ARRY-797","Arry-797"],"linkedTargets":{"rows":["ENSG00000112062"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_0010072","EFO_0003898","EFO_0004616","EFO_0000407"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL113150","canonicalSmiles":"CCCCCCCCCCCCCC[N+](C)(C)C.[Br-]","inchiKey":"CXRFDZFCGOPDTD-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CETRIMIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1180003","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anglian","Bactrian","Bansor","Ceanel","Cetavlex","Cetavlon","Cetavlon pc","Cradocap","Medicaid","Richmond","Toracsol"],"synonyms":["Cetrimide","Cetrimide bromide","Cetrimidum","Lissolamine v","Quammonium","Suticide","Tetradonium bromide"],"crossReferences":{"DrugCentral":["4360"],"PubChem":["144205880","144212384","170466276"],"Wikipedia":["Cetrimonium_bromide"],"chEBI":["3565"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL1200326","canonicalSmiles":"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl","inchiKey":"AIKVCUNQWYTVTO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NICARDIPINE HYDROCHLORIDE","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1484","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cardene","Cardene sr","Nicardipine hydrochloride"],"synonyms":["Barizin","Cardepine","Dacarel","Lecibra","Lecibral","Lescodil","Loxen","NSC-757855","Nerdipina","Nicant","Nicapress","Nicardal","Nicardipine hcl","Nicardipine hydrochloride","Nicarpin","Nicodel","Nimicor","Perdipina","Perdipine","RS-69216","RS-69216-XX-07-0","RS-69216XX07-0","Ranvil","Ridene","Rycarden","Rydene","Vasodin","Vasonase","YC-93"],"crossReferences":{"DailyMed":["nicardipine%20hydrochloride"],"PubChem":["144212149","26747578","26747579","50106640","50106641","50106642"]},"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000102001","ENSG00000151067"],"count":4},"linkedDiseases":{"rows":["EFO_0005669","EFO_0000319","EFO_1000994","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for hypertension and has 3 investigational indications."}
{"id":"CHEMBL1200383","canonicalSmiles":"CN1[C@H]2CC[C@@H]1C[C@H](OC(c1ccccc1)c1ccccc1)C2.CS(=O)(=O)O","inchiKey":"CPFJLLXFNPCTDW-BWSPSPBFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENZTROPINE MESYLATE","yearOfFirstApproval":1954,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201203","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Benztropine mesylate","Cogentin"],"synonyms":["Benzatropine mesilate","Benztropine mesilate","Benztropine mesylate","Benztropine methanesulfonate","NSC-169913"],"crossReferences":{"DailyMed":["benztropine%20mesylate"],"PubChem":["144203579"],"chEBI":["3049"]},"linkedTargets":{"rows":["ENSG00000168539"],"count":1},"linkedDiseases":{"rows":["MONDO_0005180","EFO_0009387","HP_0003418","HP_0000713"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for parkinson disease and has 2 investigational indications."}
{"id":"CHEMBL1200493","canonicalSmiles":"CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12.Cl","inchiKey":"OLUNPKFOFGZHRT-YGCVIUNWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAFTIFINE HYDROCHLORIDE","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL626","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Exoderil","Naftifine hydrochloride","Naftin"],"synonyms":["AW 105-843","AW-105-843","NAFT-900","NAFT900","NSC-760068","Naftifine hcl","Naftifine hydrochloride"],"crossReferences":{"DailyMed":["naftifine%20hydrochloride"],"PubChem":["144204228","170464903","56463179"],"chEBI":["7452"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for tinea pedis and tinea."}
{"id":"CHEMBL1200571","drugType":"Small molecule","blackBoxWarning":true,"name":"GADOBENATE DIMEGLUMINE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Multihance","Multihance multipack"],"synonyms":["B-19036","B1903617","Gadobenate","Gadobenate dimeglumine","Gadobenic acid","Gadobenic acid meglumine","Gadobenoate dimeglumine","Meglumine gadobenate"],"crossReferences":{"DailyMed":["gadobenate%20dimeglumine"],"DrugCentral":["4471","4557"],"Wikipedia":["Gadobenic_acid"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2004. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200586","canonicalSmiles":"CCCNC(C)C(=O)Nc1ccccc1C.Cl","inchiKey":"BJPJNTKRKALCPP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRILOCAINE HYDROCHLORIDE","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1194","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Citanest","Citanest plain","Citanest plain dental","Prilocaine hydrochloride"],"synonyms":["ASTRA 1512","Citanest hydrochloride","L-67","NSC-758432","Prilocaine hcl","Prilocaine hydrochloride","Propitocaine hydrochloride","Xylonest"],"crossReferences":{"DailyMed":["prilocaine%20hydrochloride"],"PubChem":["11532855","144204064","170464697","50106902"],"chEBI":["32053"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965."}
{"id":"CHEMBL1201044","canonicalSmiles":"Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl","inchiKey":"ZIODNPFQZIHCOE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DAPIPRAZOLE HYDROCHLORIDE","yearOfFirstApproval":1990,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201216","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dapiprazole hydrochloride","Rev-eyes"],"synonyms":["AF 2139","AF-2139","Dapiprazole hcl","Dapiprazole hydrochloride","Dapiprazole monohydrochloride"],"crossReferences":{"PubChem":["144206586","170466549"]},"linkedTargets":{"rows":["ENSG00000120907"],"count":1},"linkedDiseases":{"rows":["EFO_0004190","HP_0011499"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for mydriasis and open-angle glaucoma."}
{"id":"CHEMBL1201185","canonicalSmiles":"CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O","inchiKey":"PUDHBTGHUJUUFI-SCTWWAJVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"LANREOTIDE","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Somatuline autogel","Somatuline la"],"synonyms":["Angiopeptin","Lanreotide"],"crossReferences":{"DailyMed":["lanreotide%20acetate"],"Wikipedia":["Lanreotide"]},"childChemblIds":["CHEMBL1201184"],"linkedTargets":{"rows":["ENSG00000162009","ENSG00000180616"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0000447","EFO_1001769","EFO_1001307","EFO_1001901","MONDO_0024503","HP_0002014","EFO_1001466","Orphanet_657","EFO_0004243","EFO_1001496","MONDO_0044937","MONDO_0004565","MONDO_0008315","EFO_1001471","EFO_1001485","EFO_1000478","EFO_0009431","MONDO_0002995","HP_0003074","EFO_0000182","EFO_1000852","EFO_0003769","EFO_1001095"],"count":24},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for carcinoid syndrome and acromegaly and has 22 investigational indications."}
{"id":"CHEMBL1201451","drugType":"Protein","blackBoxWarning":false,"name":"ALBUMIN HUMAN","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Albumin (Human)","Albuminar-5","Buminate","Optison","Plasbumin"],"synonyms":["Albumin","Albumin (human)","Albumin human","Albumin human. plasma-derived","Albumin microspheres, human","Albumin test","Albumin, blood","Albumin, human","Albumin,human","Albumin. plasma-derived","Albumisol","Albutein","Human albumin","Human serum albumin","Normal human serum albumin","Serum albumin"],"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for nephrosis and lung disease and has 27 investigational indications."}
{"id":"CHEMBL1201476","drugType":"Oligosaccharide","blackBoxWarning":true,"name":"ENOXAPARIN SODIUM","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Clexane","Enoxaparin sodium","Enoxaparin sodium (preservative free)","Lovenox","Lovenox (preservative free)"],"synonyms":["Enoxaparin","Enoxaparin sodium","Enoxaparin sodium salt","Klexane","PK 10169","PK-10169","RP 54563","RP-54563"],"crossReferences":{"DailyMed":["enoxaparin%20sodium"],"DrugCentral":["4879"]},"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","EFO_0000275","EFO_0005669","EFO_0000495","EFO_0002950","EFO_0003964","EFO_0005681","HP_0030242","EFO_0008585","EFO_1001375","EFO_0000544","EFO_0003144","EFO_0000712","HP_0004420","EFO_0004255","EFO_0004616","HP_0004419","HP_0004936","EFO_0000616","EFO_0002618","EFO_0000545","HP_0002140","EFO_0002916","EFO_0001645","MONDO_0008170","EFO_0004286","EFO_0007443","EFO_0001073","EFO_0003060","EFO_0000311","EFO_1000954","HP_0001907","MP_0001914","MP_0001845","EFO_0001422","MONDO_0100096","MONDO_0000831","EFO_0003827","MONDO_0005147","MONDO_0021148","EFO_0000702","EFO_0009557","EFO_0003907","EFO_0008583","EFO_0000612","EFO_0000574","EFO_0009314","EFO_0000668","EFO_0005672"],"count":49},"description":"Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 28 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201787","canonicalSmiles":"CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1.[Cl-]","inchiKey":"HPKFFZSXDWPVLX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAPYRIUM CHLORIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201786","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["E-607","Emcol e-607","Lapirium chloride","Lapyrium chloride","NSC-33659"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1214827","canonicalSmiles":"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O","inchiKey":"IFRGXKKQHBVPCQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ONALESPIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ATI-13387X","ATI13387X","At-13387","At13387","Onalespib"],"crossReferences":{"drugbank":["DB06306"]},"childChemblIds":["CHEMBL3301599"],"linkedTargets":{"rows":["ENSG00000080824","ENSG00000096384"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254","EFO_0000305","MONDO_0008315","EFO_0003060"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1230438","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CCC2=O","inchiKey":"RAJWOBJTTGJROA-WZNAKSSCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1230438","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01561"],"chEBI":["15994"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1230742","canonicalSmiles":"COc1cc(-c2ccc(OC)nc2)c2oc(NS(=O)(=O)c3cc(Cl)ccc3Cl)nc2c1","inchiKey":"KOKQLKWXOFRTHE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1230742","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07321"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231700","canonicalSmiles":"C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O","inchiKey":"RZZPDXZPRHQOCG-OJAKKHQRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CITICOLINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cytidine-5'-Diphosphocholine"],"crossReferences":{"drugbank":["DB12153"],"chEBI":["16436"]},"childChemblIds":["CHEMBL1256994"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1233457","canonicalSmiles":"CCCCCCCCC[C@@H](O)CC(=O)O","inchiKey":"MUCMKTPAZLSKTL-LLVKDONJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"3-Hydroxylauric Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3-Hydroxylauric Acid"],"crossReferences":{"drugbank":["DB07930"],"chEBI":["43197"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235110","canonicalSmiles":"Cc1cccc(Nc2nc(N[C@@H]3CCCC[C@@H]3N)ncc2C(N)=O)c1","inchiKey":"NZNTWOVDIXCHHS-LSDHHAIUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1235110","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08361"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1286","canonicalSmiles":"CC[C@@H](C(N)=O)N1CCCC1=O","inchiKey":"HPHUVLMMVZITSG-LURJTMIESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVETIRACETAM","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Desitrend","Elepsia xr","Keppra","Keppra xr","Levetiracetam","Levetiracetam in sodium chloride","Matever","Spritam"],"synonyms":["AGB-101","Elepsia","Levetiracetam","Levetiracetam accord","Levetiracetam actavis","Levetiracetam hospira","Levetiracetam sun","Levetiracetam teva","Levetiracetame","N03AX14","NSC-760119","UCB 22059","UCB L059","UCB-22059","UCB-L059"],"crossReferences":{"DailyMed":["levetiracetam"],"PubChem":["26719810","90341134"],"Wikipedia":["Levetiracetam"],"drugbank":["DB01202"],"chEBI":["6437"]},"linkedTargets":{"rows":["ENSG00000159164","ENSG00000148408"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0003086","EFO_0002610","EFO_0004262","MONDO_0041052","EFO_0004280","Orphanet_232","EFO_0004777","HP_0000726","EFO_0005669","MONDO_0002046","EFO_0009562","HP_0100543","EFO_0000474","Orphanet_1945","EFO_0000289","MONDO_0002050","EFO_0004263","MONDO_0005180","EFO_0000712","Orphanet_141","EFO_0000326","MONDO_0007079","EFO_0004242","EFO_0005230","HP_0002121","HP_0002069","EFO_0008526","HP_0000473","EFO_1000904","EFO_0000222","EFO_0005407","MONDO_0015643","HP_0002381","HP_0001250","EFO_0001358","EFO_0003843","EFO_0000621","EFO_0000713","MONDO_0005301","EFO_0004895","MONDO_0004975","Orphanet_93958","EFO_0005611","EFO_0007262","EFO_0004270","EFO_0003108","EFO_0000519","EFO_0003833"],"count":49},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 38 investigational indications."}
{"id":"CHEMBL1332032","canonicalSmiles":"CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O","inchiKey":"RMWVZGDJPAKBDE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIFLUSAL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Triflusal"],"crossReferences":{"PubChem":["11112328","144203987"],"Wikipedia":["Triflusal"],"drugbank":["DB08814"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1366","drugType":"Small molecule","blackBoxWarning":true,"name":"AURANOFIN","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ridaura"],"synonyms":["Auranofin","NSC-321521","SK&F 39162","SK&F-39162","SK-39162"],"crossReferences":{"DailyMed":["auranofin"],"DrugCentral":["4122"],"Wikipedia":["Auranofin"],"chEBI":["2922"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for rheumatoid arthritis and rheumatic disease and has 11 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1371","canonicalSmiles":"O=c1[nH]c2cc(Cl)ccc2o1","inchiKey":"TZFWDZFKRBELIQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLORZOXAZONE","yearOfFirstApproval":1958,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chlorzoxazone","Paraflex","Parafon","Parafon Forte","Parafon forte dsc","Parafon-Forte","Strifon","Strifon forte dsc"],"synonyms":["Chlorzoxazone","NSC-26189"],"crossReferences":{"DailyMed":["chlorzoxazone"],"PubChem":["11110945","11110946","144203656","170464957","50106005","8139927","85230968","90340987"],"Wikipedia":["Chlorzoxazone"],"drugbank":["DB00356"],"chEBI":["3655"]},"linkedTargets":{"rows":["ENSG00000104783"],"count":1},"linkedDiseases":{"rows":["MONDO_0002046","EFO_1000786","EFO_0004616","EFO_0003843"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958."}
{"id":"CHEMBL140","canonicalSmiles":"COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O","inchiKey":"VFLDPWHFBUODDF-FCXRPNKRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL140","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["104171337","124882763","124882764","124882767","144204354","144205058","144208314","17389087","50104137","50104138","56422380","855880","91276"],"drugbank":["DB11672"],"chEBI":["3962"]},"childChemblIds":["CHEMBL1916041"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL14309","canonicalSmiles":"CCC(=O)O[C@@]1(c2ccccc2)CCN(C)C[C@H]1C","inchiKey":"UVAZQQHAVMNMHE-CJNGLKHVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALPHAPRODINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"Wikipedia":["Prodine"],"drugbank":["DB13160"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1433","canonicalSmiles":"C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21","inchiKey":"JBIWCJUYHHGXTC-AKNGSSGZSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DOXYCYCLINE ANHYDROUS","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Anhydrous doxycycline","Doxycycline (anhydrous)"],"crossReferences":{"DailyMed":["doxycycline","doxycycline%20hyclate"],"PubChem":["26755247","90340791"],"Wikipedia":["Doxycycline"],"drugbank":["DB00254"],"chEBI":["50845"]},"childChemblIds":["CHEMBL1200699","CHEMBL2364574","CHEMBL1256723","CHEMBL1200567","CHEMBL2106418","CHEMBL3989740"],"linkedTargets":{"rows":["ENSG00000196611","ENSG00000137745","ENSG00000118113","ENSG00000137673"],"count":4},"linkedDiseases":{"rows":["EFO_0000729","EFO_1000842","EFO_0000365","EFO_0007486","EFO_0000756","EFO_0009536","EFO_0007272","EFO_0005952","EFO_0003102","Orphanet_85443","EFO_1001951","EFO_0007205","EFO_0000771","EFO_1001459","EFO_0000096","EFO_0000544","EFO_1001898","EFO_0007357","EFO_1000961","EFO_0008517","EFO_1000785","MONDO_0002635","EFO_0002618","EFO_1001235","EFO_0007504","EFO_0002687","EFO_1000906","HP_0000964","MONDO_0022113","EFO_1001466","Orphanet_3389","EFO_0000662","EFO_0004607","Orphanet_558","EFO_0000384","EFO_0003878","EFO_1001444","EFO_1001388","EFO_1000760","MP_0001914","EFO_0007460","MONDO_0100096","EFO_0007430","HP_0000130","EFO_1001177","DOID_7551","EFO_0000574","EFO_0009659","EFO_1001051","EFO_0000341","EFO_1001312","Orphanet_314701","EFO_0009637","EFO_0004214","EFO_1001896","EFO_0001365","EFO_1001984","EFO_0009117","EFO_0000768","EFO_0002913","Orphanet_586","EFO_0011048","EFO_0000274","EFO_0003955","Orphanet_85451","EFO_0005622","EFO_0008510","EFO_0009425","HP_0002013","EFO_0000778","EFO_0000694","EFO_1001788","HP_0001945","EFO_1001875","EFO_0003770","EFO_0000319","Orphanet_271861","HP_0001250","EFO_0003894","EFO_1002047","EFO_1000941","EFO_0003060","EFO_0003843","EFO_0000311","EFO_0003106","MONDO_0005301","EFO_0001068","EFO_0000649","EFO_0000764","Orphanet_774","MONDO_0004975","EFO_0000199","EFO_1000781","EFO_0007410","EFO_0000612","MONDO_0043510","EFO_0001067","EFO_0007185","MONDO_0024880","MONDO_0005178","EFO_0007480","EFO_0003895"],"count":102},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 67 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1456","canonicalSmiles":"COc1c(C)c2c(c(O)c1C/C=C(\\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2","inchiKey":"RTGDFNSFWBGLEC-SYZQJQIISA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MYCOPHENOLATE MOFETIL","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Arzip","Cellcept","Mycophenolate mofetil","Myfenax"],"synonyms":["Myclausen","Mycophenolate mofetil","Mycophenolic acid 2-(4-morpholinyl)ethyl ester","Mycophenylate mofetil","NSC-724229","NSC-758905","RS-61443"],"crossReferences":{"DailyMed":["mycophenolate%20mofetil","mycophenolate%20mofetil%20hydrochloride"],"PubChem":["144205239","170464859","29215409"],"Wikipedia":["Mycophenolate_mofetil"],"drugbank":["DB00688"],"chEBI":["8764"]},"childChemblIds":["CHEMBL1200955"],"linkedTargets":{"rows":["ENSG00000106348","ENSG00000178035"],"count":2},"linkedDiseases":{"rows":["EFO_0004228","EFO_0000681","EFO_0000401","EFO_0005952","EFO_1001345","EFO_0006803","EFO_1000318","MONDO_0015760","EFO_0000339","EFO_0000096","EFO_0002690","EFO_1000956","Orphanet_3319","EFO_0003884","EFO_0000676","MONDO_0004976","EFO_0004991","Orphanet_42738","EFO_0000198","MONDO_0013730","EFO_0002618","EFO_0009012","MONDO_0019465","EFO_0001642","EFO_1000309","EFO_0000384","Orphanet_567","EFO_1001231","HP_0002721","MONDO_0009453","EFO_0000404","EFO_0003032","MONDO_0044889","MONDO_0019472","EFO_0000574","EFO_0004256","EFO_0001378","Orphanet_231214","EFO_1000550","EFO_0001062","Orphanet_84","EFO_0003086","MONDO_0044903","EFO_0001365","EFO_0007451","EFO_1001465","EFO_0000255","MONDO_0003541","EFO_0002430","EFO_0005676","MONDO_0002898","Orphanet_79264","EFO_0007208","EFO_0004826","EFO_0000183","EFO_0005140","Orphanet_447","EFO_1000388","HP_0012115","EFO_0000616","EFO_1001779","EFO_1001017","MONDO_0019457","EFO_0000403","EFO_0000222","MONDO_0000870","EFO_0000319","MONDO_0018170","MONDO_0019469","EFO_0004599","EFO_0000537","EFO_0003896","Orphanet_79292","EFO_0005297","EFO_0000764","EFO_0007359","EFO_0006927","EFO_0000702","MONDO_0002367","MONDO_0018906","EFO_0000519","Orphanet_309015","MONDO_0000873","EFO_0003777","Orphanet_183660","EFO_0004274","Orphanet_848","EFO_0000565","EFO_0000309","EFO_0007160","EFO_0004251","EFO_1000680","HP_0001871","MONDO_0019088","EFO_0000389","EFO_0000182","EFO_0000330","EFO_0004255","EFO_0004244","EFO_0007196","EFO_1000785","EFO_0004719","EFO_0009441","EFO_0005761","EFO_1001857","EFO_0000220","EFO_0004236","EFO_0004194","MONDO_0044881","EFO_1000784","EFO_0002429","MONDO_0019474","Orphanet_811","MP_0001845","MONDO_0021193","EFO_0002428","EFO_1001051","MONDO_0002334","EFO_0000699","EFO_0009878","EFO_1000102","MONDO_0019471","Orphanet_232","EFO_1000965","EFO_0008507","DOID_13406","EFO_1001469","HP_0001915","EFO_0000274","EFO_1002048","EFO_1000690","Orphanet_906","EFO_0004254","EFO_0003047","EFO_0000717","EFO_0000685","EFO_0000621","EFO_0000311","MONDO_0001705","EFO_0000211","MONDO_0005301","EFO_0000095","MONDO_0005147","EFO_0001421","EFO_1000560"],"count":145},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 119 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1521495","canonicalSmiles":"O=C1CN=C(c2ccccc2)c2c(sc3c2CCCC3)N1","inchiKey":"AIZFEOPQVZBNGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENTAZEPAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bentazepam","CI-718"],"crossReferences":{"PubChem":["50085894"],"drugbank":["DB14719"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1534525","canonicalSmiles":"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C.Cl.Cl","inchiKey":"MTJLQTFHJIHXIX-GDUXWEAWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIBEFRADIL DIHYDROCHLORIDE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL45816","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," European Union"," Germany"," Ireland"," Malasia"],"classes":["Cardiotoxicity"],"year":1998},"tradeNames":["Posicor"],"synonyms":["Mibefradil dihydrochloride","Mibefradil hydrochloride","RO 40-5967/001"],"crossReferences":{"PubChem":["144204795","170466110","50106572"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997. It was withdrawn in United States,  European Union,  Germany,  Ireland and  Malasia initially in 1998 due to Cardiotoxicity."}
{"id":"CHEMBL1615439","canonicalSmiles":"C[C@H]1[C@H](c2ccccc2)OCCN1C","inchiKey":"MFOCDFTXLCYLKU-CMPLNLGQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENDIMETRAZINE","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-169187","Phendimetrazine"],"crossReferences":{"DailyMed":["phendimetrazine%20tartrate"],"drugbank":["DB01579"],"chEBI":["8059"]},"childChemblIds":["CHEMBL2062163"],"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["EFO_0010445","EFO_0001073"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity."}
{"id":"CHEMBL168083","canonicalSmiles":"Cc1ccc(C(=O)N(c2cc(-c3ccccc3)sc2C(=O)O)C(C)C)cc1","inchiKey":"LRHXIDOGMBZJFN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL168083","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03647"],"chEBI":["43541"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1697760","canonicalSmiles":"CC(c1ccc(Cl)c(Cl)c1)N1N=C(N)CC1=O","inchiKey":"RLWRMIYXDPXIEX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MUZOLIMINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["European Union"," Germany"," France"],"classes":["Neurotoxicity"],"year":1987},"tradeNames":[],"synonyms":["BAY G 2821","BAY-G 2821","BAY-G-2821","Edrul","Muzolimine"],"crossReferences":{"drugbank":["DB13801"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in European Union,  Germany and  France initially in 1987 due to Neurotoxicity."}
{"id":"CHEMBL1706","canonicalSmiles":"Cl.c1ccc2c(CC3=NCCN3)cccc2c1","inchiKey":"DJDFFEBSKJCGHC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAPHAZOLINE HYDROCHLORIDE","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL761","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Albalon","Antistin-privine","Gppe nsl soln","Nafazair","Naphaz hcl","Naphazoline hydrochloride","Naphcon","Naphcon forte","Opcon","Vasocon"],"synonyms":["NSC-35711","Naphazoline HCl","Naphazoline hcl","Naphazoline hydrochloride","Naphazoline nitrate"],"crossReferences":{"DailyMed":["naphazoline%20hydrochloride"],"PubChem":["56422379","855777"],"chEBI":["7470"]},"linkedTargets":{"rows":["ENSG00000274286","ENSG00000184160","ENSG00000171873","ENSG00000170214","ENSG00000120907","ENSG00000150594"],"count":6},"linkedDiseases":{"rows":["MP_0001845","EFO_0007486","EFO_0000678","EFO_0007328","EFO_0007141","HP_0001742","EFO_0007214","EFO_0003956"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 3 investigational indications."}
{"id":"CHEMBL1723241","canonicalSmiles":"CC(=O)[N-]S(=O)(=O)c1ccc(N)cc1.O.[Na+]","inchiKey":"IHCDKJZZFOUARO-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFACETAMIDE SODIUM","yearOfFirstApproval":1961,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL455","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Albucid","Bleph","Bleph-10","Bleph-30","Cetamide","Isopto cetamide","Klaron","Novacet","Ocusol","Ocusulf","Ocusulf-10","Ocusulf-30","Sodium sulamyd","Sodium sulfacetamide","Sulf-10","Sulf-15","Sulfacel","Sulfacel-15","Sulfacetamide sodium","Sulfair 10","Sulfair forte","Sulfair-15","Sulten-10"],"synonyms":["Flammazine","NSC-625324","Sodium sulfacetamide, anhydrous","Sulfacetamide sodium","Sulfacetamide sodium anhydrous","Sulfacetamide sodium salt","Sulfacetamide sodium salt monohydrate","Sulfacetamidum natricum","Sulphacetamide sodium"],"crossReferences":{"DailyMed":["sulfacetamide%20sodium"],"PubChem":["11112977","56463335"],"chEBI":["63858"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for acne and inflammation."}
{"id":"CHEMBL1743031","drugType":"Antibody","blackBoxWarning":false,"name":"INDATUXIMAB RAVTANSINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BT-062","Indatuximab ravtansine"],"linkedTargets":{"rows":["ENSG00000115884"],"count":1},"linkedDiseases":{"rows":["EFO_0001378"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1788385","canonicalSmiles":"Cc1cc(Br)c(O)c2ncccc12","inchiKey":"JMOVFFLYGIQXMM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TILBROQUINOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tilbroquinol"],"crossReferences":{"Wikipedia":["Tilbroquinol"],"drugbank":["DB13222"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL188343","canonicalSmiles":"c1nc2c(NC3CCCCC3)nc(Nc3ccc(N4CCOCC4)cc3)nc2[nH]1","inchiKey":"ZFLJHSQHILSNCM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"REVERSINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Reversine"],"crossReferences":{"PubChem":["174007245","29217638"],"drugbank":["DB07340"],"chEBI":["70723"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1905073","canonicalSmiles":"Nc1ccc(S(=O)(=O)Nc2cnc3c(Cl)cccc3n2)cc1","inchiKey":"CTSNHMQGVWXIEG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLORSULFAQUINOXALINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Chloroquinoxaline sulfonamide","Chlorsulfaquinoxaline","NSC-339004"],"crossReferences":{"PubChem":["461007","92763856"],"drugbank":["DB12921"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1908307","canonicalSmiles":"Cn1cc([S+](C)[O-])c(=O)c2ccc(F)cc21","inchiKey":"UYGONJYYUKVHDD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLOSEQUINAN","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"],"year":1993},"tradeNames":["Manoplax"],"synonyms":["BTS 49 465","BTS-49-465","BTS-49465","Flosequinan"],"crossReferences":{"PubChem":["144206866"],"drugbank":["DB13228"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and is indicated for cardiovascular disease. It was withdrawn in United Kingdom and  United States initially in 1993."}
{"id":"CHEMBL1952329","canonicalSmiles":"CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1","inchiKey":"MHXGEROHKGDZGO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SGI-1776","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SGI-1776","Sgi-1776"],"crossReferences":{"PubChem":["137276030"],"drugbank":["DB12494"]},"childChemblIds":["CHEMBL1952141"],"linkedTargets":{"rows":["ENSG00000102096","ENSG00000137193","ENSG00000198355"],"count":3},"linkedDiseases":{"rows":["EFO_0000565","EFO_0005952","MONDO_0008315"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2022411","canonicalSmiles":"CCC(=O)N(c1ccccc1)C1CCN(C(C)Cc2ccccc2)CC1","inchiKey":"NGTVDHYUFBKWID-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Alpha-Methylfentanyl","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alpha-Methylfentanyl"],"crossReferences":{"drugbank":["DB01557"]},"childChemblIds":["CHEMBL3188385"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2037511","canonicalSmiles":"CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C","inchiKey":"UWHCWRQFNKUYCG-QUZACWSFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPELSIBAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epelsiban","GSK-557296","GSK557296","GSK557296B","Gsk557296"],"crossReferences":{"drugbank":["DB11934"]},"childChemblIds":["CHEMBL2105736"],"linkedTargets":{"rows":["ENSG00000180914"],"count":1},"linkedDiseases":{"rows":["EFO_1001757"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2103863","canonicalSmiles":"CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12","inchiKey":"MAUCONCHVWBMHK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ABEXINOSTAT","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Abexinostat","CRA 024781","CRA 24781","CRA-024781","PCI 24781","PCI-24781","PZP-115891","PZP115891","S-78454","S78454"],"crossReferences":{"drugbank":["DB12565"]},"childChemblIds":["CHEMBL2105727"],"linkedTargets":{"rows":["ENSG00000108840","ENSG00000094631","ENSG00000061273","ENSG00000068024","ENSG00000147099","ENSG00000116478","ENSG00000100429","ENSG00000163517","ENSG00000171720","ENSG00000048052","ENSG00000196591"],"count":11},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000681","EFO_0000403","MONDO_0018906","EFO_0000183","EFO_0005952","EFO_0000691"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL2104588","canonicalSmiles":"COP(=S)(OC)Oc1ccc(S(N)(=O)=O)cc1","inchiKey":"BSBSDQUZDZXGFN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYTHIOATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cythioate","NSC-310287"],"crossReferences":{"PubChem":["144206631"],"drugbank":["DB11392"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2104616","canonicalSmiles":"CCN(CC)CCn1c(Cc2ccc(Cl)cc2)nc2cc([N+](=O)[O-])ccc21","inchiKey":"GPZLDQAEBHTMPG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLONITAZENE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Acscn-9612","C-193901","Clobedolum","Clonitazene","IDS-NC-002"],"crossReferences":{"drugbank":["DB01523"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106571","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CCC4=C(Cl)C(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O","inchiKey":"KCZCIYZKSLLNNH-FBPKJDBXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOSTEBOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-chlorotestosterone","Clostebol","Clostebol acetate","Macrobin","NSC-72159","Steranabol"],"crossReferences":{"PubChem":["144205410"],"drugbank":["DB01521"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106622","canonicalSmiles":"N[C@@H](Cc1cc([131I])c(Oc2ccc(O)c([131I])c2)c([131I])c1)C(=O)O","inchiKey":"AUYYCJSJGJYCDS-UMVFHIKJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LIOTHYRONINE I 131","maximumClinicalTrialPhase":1,"parentId":"CHEMBL1544","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Tri-thyrotope","Triomet-131"],"synonyms":["Liothyronine i 131","Liothyronine i-131"],"crossReferences":{"drugbank":["DB12425"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107143","canonicalSmiles":"O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O","inchiKey":"PSVUJBVBCOISSP-SPFKKGSWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLUFOSFAMIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["D 19575","D-19575","Glucosylifosfamide mustard","Glufosfamide"],"crossReferences":{"drugbank":["DB06177"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL2107553","canonicalSmiles":"O=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1","inchiKey":"ODKYYBOHSVLGNU-IAGONARPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TERIZIDONE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Terizidone"],"crossReferences":{"drugbank":["DB12954"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2107725","canonicalSmiles":"Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)c4ccc(C(=N)N)cc4)c3Cl)c2n1","inchiKey":"XUHBBTKJWIBQMY-MHZLTWQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANATIBANT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anatibant","Lf16-0687","XY-2405","XY2405"],"crossReferences":{"drugbank":["DB05038"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2108055","drugType":"Antibody","blackBoxWarning":false,"name":"TEFIBAZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Aurexis"],"synonyms":["INH-H2002","INHH-2002","Tefibazumab"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2108147","drugType":"Enzyme","blackBoxWarning":false,"name":"STREPTOKINASE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kabikinase","Streptase"],"synonyms":["Streptokinase","Streptokinase c"],"linkedTargets":{"rows":["ENSG00000122194"],"count":1},"linkedDiseases":{"rows":["HP_0002140","EFO_1001375","EFO_0003827","EFO_1000652","EFO_0008583","EFO_0000612","HP_0004419","EFO_0009637","HP_0004936"],"count":9},"description":"Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for recurrent thrombophlebitis and has 6 investigational indications."}
{"id":"CHEMBL2108268","drugType":"Unknown","blackBoxWarning":false,"name":"CELLULOSE, OXIDIZED","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Oxycel","Surgicel"],"synonyms":["Cellulose, absorbable","Cellulose, oxidized","Oxidised cellulose"],"description":"Unknown drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2108525","drugType":"Small molecule","blackBoxWarning":false,"name":"POLYFEROSE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Jefron"],"synonyms":["Iron carbohydrate complex","Polyferose"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109321","drugType":"Antibody","blackBoxWarning":false,"name":"CAROTUXIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carotuximab","DE-122","TRC-105","Trc105","c-SN6j"],"linkedTargets":{"rows":["ENSG00000106991"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0001365","EFO_0000681","EFO_0000349","EFO_1001465","MONDO_0007254","EFO_1001968","EFO_0002501","EFO_0003060","MONDO_0008315","EFO_0000311","EFO_0009708","EFO_0000640","EFO_0003968","MONDO_0003268","MONDO_0008903","EFO_0000182","EFO_0002499","EFO_1001111","EFO_0002893","EFO_0000519"],"count":21},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications."}
{"id":"CHEMBL2109643","drugType":"Antibody","blackBoxWarning":false,"name":"F19 131I","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIBH-1","F19","F19 131i"],"linkedTargets":{"rows":["ENSG00000078098"],"count":1},"linkedDiseases":{"rows":["EFO_0007175","EFO_1001951"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2110580","canonicalSmiles":"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1","inchiKey":"FIGNGSHKNAHTSH-JJMFXPFOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BERUBICIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Berubicin"],"childChemblIds":["CHEMBL2103796"],"linkedTargets":{"rows":["ENSG00000131747","ENSG00000077097"],"count":2},"linkedDiseases":{"rows":["MONDO_0100342","EFO_0000326","EFO_0000313","EFO_0000519"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2110816","canonicalSmiles":"CC(CC1c2ccccc2CCc2ccccc21)CN(C)C","inchiKey":"ALELTFCQZDXAMQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTRIPTYLINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Evadene","Evadyne"],"synonyms":["Butriptyline"],"crossReferences":{"PubChem":["170466439"],"drugbank":["DB09016"]},"childChemblIds":["CHEMBL2106170"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for unipolar depression."}
{"id":"CHEMBL2111029","canonicalSmiles":"N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O","inchiKey":"LLEUXCDZPQOJMY-AAEUAGOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OGLUFANIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-334073","Oglufanide"],"crossReferences":{"drugbank":["DB05779"],"chEBI":["73512"]},"childChemblIds":["CHEMBL2107123"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2137530","canonicalSmiles":"c1ccc2c(CCNc3ccc(Nc4ccncc4)cc3)c[nH]c2c1","inchiKey":"CEGSUKYESLWKJP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SERDEMETAN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ-26854165","Serdemetan"],"crossReferences":{"PubChem":["137276015"],"drugbank":["DB12027"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL214253","canonicalSmiles":"O=C1NC(=O)c2c1c(-c1ccccc1)cc1[nH]c3ccc(O)cc3c21","inchiKey":"IAUZTOZLTFSMIE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PD-407824","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PD-407824"],"crossReferences":{"PubChem":["50112977"],"drugbank":["DB04608"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL218490","canonicalSmiles":"CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21","inchiKey":"IAVUPMFITXYVAF-XPUUQOCRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DORZOLAMIDE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dorzant","Trusopt"],"synonyms":["Dorzolamide","Dorzolamide, trans-(-)-","MK-507","Trusopt"],"crossReferences":{"DailyMed":["dorzolamide%20hydrochloride"],"Wikipedia":["Dorzolamide"],"drugbank":["DB00869"],"chEBI":["4702"]},"childChemblIds":["CHEMBL1201162"],"linkedTargets":{"rows":["ENSG00000104267"],"count":1},"linkedDiseases":{"rows":["EFO_0003966","EFO_0004190","EFO_1001069","EFO_0004683","EFO_0000516","EFO_0009321"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 3 investigational indications."}
{"id":"CHEMBL2203744","canonicalSmiles":"CN(C(=S)NN=C(c1ccccn1)c1ccccn1)C1CCCCC1","inchiKey":"GNLZNQJBZNOUBM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2203744","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB15235"]},"childChemblIds":["CHEMBL2203739"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2338675","canonicalSmiles":"Nc1nc2c(c(=O)[nH]1)N[C@@H]1[C@H](N2)O[C@@H]2COP(=O)(O)O[C@@H]2C1(O)O","inchiKey":"CZAKJJUNKNPTTO-AJFJRRQVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSDENOPTERIN","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["ALXN-1101 ANHYDROUS FREE BASE","ALXN1101","C(pmp)","Fosdenopterin","Precursor z"],"crossReferences":{"chEBI":["60210"]},"childChemblIds":["CHEMBL4594300","CHEMBL2338674"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for sulfite oxidase deficiency due to molybdenum cofactor deficiency type a."}
{"id":"CHEMBL233992","canonicalSmiles":"O=C(N[C@H]1CCC[C@H]1NC(=O)c1ccc(Cl)s1)c1ccc(-n2ccccc2=O)cc1","inchiKey":"QCPYHSAHOYXXQK-DLBZAZTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL233992","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08174"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL235157","canonicalSmiles":"COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC","inchiKey":"NVINUNQBDNEMSY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL235157","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["103905635"],"drugbank":["DB06932"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL259209","canonicalSmiles":"CCN(CC)C(=O)C1(c2ccccc2)CC1CN","inchiKey":"GJJFMKBJSRMPLA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MILNACIPRAN","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Impulsor","Midalcipran","Milnacipran"],"crossReferences":{"DailyMed":["milnacipran%20hydrochloride"],"drugbank":["DB04896"]},"childChemblIds":["CHEMBL4297064","CHEMBL3527085"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546"],"count":2},"linkedDiseases":{"rows":["EFO_0005762","EFO_0000685","EFO_0005687","EFO_0000555","EFO_0003757","HP_0003418","EFO_0003843","MONDO_0100431","MONDO_0005277","MONDO_0002050","HP_0030834","EFO_0003100","EFO_0003761","HP_0003419","MONDO_0005178","MONDO_0005475"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL262628","canonicalSmiles":"NNC(=O)c1[nH]c2ccc(S(N)(=O)=O)cc2c1-c1ccccc1","inchiKey":"PPDLAUCFAOODER-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL262628","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08659"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL271475","canonicalSmiles":"O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2F)cc1I","inchiKey":"IPVFGAYTKQKGBM-BYPJNBLXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FIALURIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fialuridine","Fiau","NSC-678514"],"crossReferences":{"Wikipedia":["Fialuridine"],"drugbank":["DB15427"]},"childChemblIds":["CHEMBL493085","CHEMBL213723"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL283807","canonicalSmiles":"Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1","inchiKey":"RQFCJASXJCIDSX-UUOKFMHZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL283807","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01972"],"chEBI":["17345"]},"childChemblIds":["CHEMBL1627076"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL284838","canonicalSmiles":"O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O","inchiKey":"ULGNGSQNNMKROG-WOJBJXKFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"K-134","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["K-134","OPC-33509"],"crossReferences":{"drugbank":["DB12685"]},"linkedTargets":{"rows":["ENSG00000152270","ENSG00000172572"],"count":2},"linkedDiseases":{"rows":["EFO_0003876"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL290962","canonicalSmiles":"CCCN1C[C@@H](NS(=O)(=O)N(CC)CC)C[C@@H]2Cc3c(O)cccc3C[C@H]21","inchiKey":"GDFGTRDCCWFXTG-ZIFCJYIRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUINAGOLIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Norprolac"],"crossReferences":{"Wikipedia":["Quinagolide"],"drugbank":["DB09097"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL291278","canonicalSmiles":"CN[C@H](CC(=O)O)C(=O)O","inchiKey":"HOKKHZGPKSLGJE-GSVOUGTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"N-METHYL-D-ASPARTIC ACID (NMDA)","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(R)-2-(Methylamino)Succinic Acid","2-Methylamino-Succinic Acid","N-Methyl-Daspartate","N-methyl-d-aspartic acid (nmda)","Nmda"],"crossReferences":{"PubChem":["11111449","11113384","26751633","46500421","50104312","50104313","50104314","90341063"],"Wikipedia":["N-Methyl-D-aspartic_acid"],"chEBI":["31882"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL301742","canonicalSmiles":"NC[C@H](CC(=O)O)c1ccc(Cl)cc1","inchiKey":"KPYSYYIEGFHWSV-QMMMGPOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARBACLOFEN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(r)-baclofen","Arbaclofen","Baclofen (r)-form","Baclofen, (r)-","Baclofen, r(-)-","Baclofen, r-","D-baclofen","R-(-)-baclofen","STX-209","STX209"],"crossReferences":{"PubChem":["11113710"],"drugbank":["DB08891"]},"linkedTargets":{"rows":["ENSG00000136928","ENSG00000204681"],"count":2},"linkedDiseases":{"rows":["HP_0001257","EFO_0003756","Orphanet_908"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3137353","drugType":"Antibody","blackBoxWarning":false,"name":"BIMAGRUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BYM-338","BYM338","Bimagrumab","O81t794r34"],"linkedTargets":{"rows":["ENSG00000114739"],"count":1},"linkedDiseases":{"rows":["EFO_1000653","EFO_0009851","EFO_0007323","HP_0004326","EFO_0000341","MONDO_0005148"],"count":6},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL321113","canonicalSmiles":"O=C(O)Cc1ccc2c(c1O)C(=O)c1c(O)cccc1C2","inchiKey":"IXLRLZOYKJERRA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL321113","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02019"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3301592","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM ZIRCONIUM CYCLOSILICATE","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lokelma"],"synonyms":["Sodium zirconium cyclosilicate","UXSi-9","ZS","ZS-9"],"crossReferences":{"DailyMed":["sodium%20zirconium%20cyclosilicate"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for hyperkalemia and has 1 investigational indication."}
{"id":"CHEMBL338802","canonicalSmiles":"NC(N)=NS(=O)(=O)c1ccc(N)cc1","inchiKey":"BRBKOPJOKNSWSG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFAGUANIDINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gppe susp fte","Guanimycin"],"synonyms":["NSC-14041","Sulfaguanidine","Sulphaguanidine"],"crossReferences":{"PubChem":["11112136","144203880","170465708","856017"],"drugbank":["DB13726"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL34412","canonicalSmiles":"Nc1nc2c(c(=O)[nH]1)C[C@@H](CCc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2","inchiKey":"ZUQBAQVRAURMCL-DOMZBBRYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LOMETREXOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY264618","Lometrexol"],"crossReferences":{"drugbank":["DB12769"]},"childChemblIds":["CHEMBL2104666"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3544958","drugType":"Small molecule","blackBoxWarning":false,"name":"CER-002","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cer-002"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545064","canonicalSmiles":"CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O.CS(=O)(=O)O","inchiKey":"OXYYOEIGQRXGPI-WSZWBAFRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TALABOSTAT MESYLATE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL67279","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PT-100","Talabostat mesilate","Talabostat mesylate"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545168","drugType":"Small molecule","blackBoxWarning":false,"name":"IMD-1041","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Imd-1041"],"linkedTargets":{"rows":["ENSG00000104365"],"count":1},"linkedDiseases":{"rows":["EFO_0000341"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545235","canonicalSmiles":"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(CC2)C2(C1)OCCO2","inchiKey":"OXWUWXCJDBRCCG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SIMOTINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sim-6802","Simotinib"],"linkedTargets":{"rows":["ENSG00000146648"],"count":1},"linkedDiseases":{"rows":["EFO_0003060"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3545287","drugType":"Small molecule","blackBoxWarning":false,"name":"LY2624803","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DB-7","HY-10275","LY2624803","Ly-2624803","Ly2624803"],"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0004698"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545374","drugType":"Antibody","blackBoxWarning":false,"name":"TREVOGRUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Human igg4 anti-myostatin mab","REGN-1033","REGN1033","SAR-391786","SAR391786","Trevogrumab"],"linkedTargets":{"rows":["ENSG00000138379"],"count":1},"linkedDiseases":{"rows":["EFO_1000653","EFO_0007323"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL36255","canonicalSmiles":"COc1ccc(/C=C\\c2cc(OC)c(OC)c(OC)c2)c(O)c1O","inchiKey":"YUSYSJSHVJULID-WAYWQWQTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"COMBRETASTATIN A-1","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Combretastatin a-1","Combretastatin a1","NSC-600032","OXI4500"],"crossReferences":{"PubChem":["483048"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3707257","canonicalSmiles":"O=[N+]([O-])OCCN(CCO[N+](=O)[O-])CCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-]","inchiKey":"DLDKCSIJFIPYRK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TENITRAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tenitramine"],"crossReferences":{"drugbank":["DB13637"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3707295","drugType":"Enzyme","blackBoxWarning":false,"name":"REVEGLUCOSIDASE ALFA","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMN 701","BMN-701","Gilt-rhgaa","Reveglucosidase alfa","ZC-701"],"description":"Enzyme drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL3707303","canonicalSmiles":"O=C([O-])[C@@H]1CCC(O)=N1.O=C([O-])[C@@H]1CCC(O)=N1.[Mg+2]","inchiKey":"JQAACYUZYRBHGG-QHTZZOMLSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"MAGNESIUM PIDOLATE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL397976","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Magnesium pca","Magnesium pidolate","Magnesium pyroglutamate"],"crossReferences":{"DrugCentral":["4597"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3833303","drugType":"Small molecule","blackBoxWarning":false,"name":"FERROUS GLUCONATE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL3991443","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fergon","Sideromal"],"synonyms":["E-579","Ferrous gluconate","Ferrous gluconate dihydrate","Ferrous-gluconate","INS NO.579","INS-579","Iron (as ferrous gluconate)","Iron gluconate","Iron(ii) gluconate"],"crossReferences":{"DrugCentral":["4491"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for anemia (phenotype)."}
{"id":"CHEMBL398346","canonicalSmiles":"CCNC(=O)c1noc(-c2cc(Cl)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1","inchiKey":"APGOABVITLQCKW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL398346","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06961"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989716","canonicalSmiles":"CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1","inchiKey":"GBKONKCASNNUQD-VGHSCWAPSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PROPOXYPHENE NAPSYLATE","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1213351","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Cardiotoxicity"],"year":2014},"tradeNames":["Darvon-n"],"synonyms":["D-propoxyphene napsylate hydrate","Dextropropoxyphene napsilate","Propoxyphene napsylate","Propoxyphene napsylate cii","Propoxyphene napsylate monohydrate"],"crossReferences":{"DailyMed":["propoxyphene%20napsylate"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1971 and is indicated for pain. It was withdrawn in United States  in 2014 due to Cardiotoxicity. This drug has a black box warning from the FDA."}
{"id":"CHEMBL404108","canonicalSmiles":"Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1","inchiKey":"KHPKQFYUPIUARC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LUMIRACOXIB","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["European Union"],"classes":["Hepatotoxicity"],"year":2007},"tradeNames":["Prexige"],"synonyms":["COX-189","Lumiracoxib"],"crossReferences":{"PubChem":["144207115","170465597"],"Wikipedia":["Lumiracoxib"],"drugbank":["DB01283"],"chEBI":["73044"]},"linkedTargets":{"rows":["ENSG00000073756"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_1000786","EFO_0004274","EFO_0004616","MONDO_0005178","EFO_0003843","EFO_0005755"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 4 investigational indications. It was withdrawn in European Union  in 2007 due to Hepatotoxicity."}
{"id":"CHEMBL416301","canonicalSmiles":"CCCCCCCCCCCC(O)(P(=O)(O)O)P(=O)(O)O","inchiKey":"KKVZONPEMODBBG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL416301","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07873"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL42423","canonicalSmiles":"O=[N+]([O-])c1ccc(O)c(O)c1","inchiKey":"XJNPNXSISMKQEX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-Nitrocatechol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Nitrocatechol"],"crossReferences":{"drugbank":["DB03407"],"chEBI":["16318"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL425584","canonicalSmiles":"N[C@@H](CC(=O)N1CCC[C@H]1CNC(=O)c1ccccc1)Cc1ccccc1F","inchiKey":"ANQHSFFUNMTTRS-MOPGFXCFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL425584","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07779"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL426560","canonicalSmiles":"O=C(O)CNC(=O)c1nc(Cl)c2ccccc2c1O","inchiKey":"OUQVKRKGTAUJQA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL426560","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08687"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297291","canonicalSmiles":"O=C(O)CCCC(=O)NCCc1c[nH]cn1","inchiKey":"KZIMLUFVKJLCCH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INGAVIRIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Imidazolyl ethanamide pentandioic acid","Ingamine","Ingavirin"],"crossReferences":{"drugbank":["DB11944"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL4297476","canonicalSmiles":"C[C@@H]1CNS(=O)(=O)N(c2ccc3c(C#N)nccc3c2)C1","inchiKey":"ZKAVFOXYJCREBQ-SNVBAGLBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-06260414","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-06260414","Pf-06260414"],"crossReferences":{"drugbank":["DB15221"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297700","drugType":"Antibody","blackBoxWarning":false,"name":"BIMEKIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bimekizumab","UCB-4940","UCB4940","Ucb4940"],"linkedTargets":{"rows":["ENSG00000112116","ENSG00000112115"],"count":2},"linkedDiseases":{"rows":["EFO_0000685","EFO_1000710","EFO_0003898","EFO_0000676","EFO_0003778"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4297884","drugType":"Antibody","blackBoxWarning":false,"name":"PEPINEMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anti-sema4d monoclonal antibody vx15/2503","Pepinemab","VX-15","VX-152503","VX15","VX15/2503","Vx15/2503"],"linkedTargets":{"rows":["ENSG00000187764"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","Orphanet_399","EFO_1000044","EFO_0000637","MONDO_0005301","EFO_0000389","MONDO_0004975","EFO_0000181","EFO_0003060"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL4298121","drugType":"Unknown","blackBoxWarning":false,"name":"KALLIKREIN-1","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Kallikrein-1","Tissue kallikrein"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4300766","canonicalSmiles":"C[C@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O","inchiKey":"NSMXQKNUPPXBRG-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"P","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297371"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4303228","canonicalSmiles":"CC(C)=CCC/C(C)=C/CC/C(C)=C/C=C/C(C)=C/C(=O)O","inchiKey":"UUBHZHZSIKRVIV-KCXSXWJSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERETINOIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nik-333","Peretinoin"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL434394","canonicalSmiles":"OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1","inchiKey":"KOHIRBRYDXPAMZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NEBIVOLOL","yearOfFirstApproval":2007,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Hypoloc","Nebilet"],"synonyms":["Narbivolol","Nebivolol","R-65824","R65,824"],"crossReferences":{"DailyMed":["nebivolol%20hydrochloride"],"Wikipedia":["Nebivolol"],"drugbank":["DB04861"],"chEBI":["64019"]},"childChemblIds":["CHEMBL1201731"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591"],"count":2},"linkedDiseases":{"rows":["EFO_0008527","EFO_0001645","EFO_0004234","EFO_0000768","EFO_0009658","EFO_0000319","Orphanet_558","EFO_0003882","EFO_0000537","EFO_0003914","EFO_0000195","MONDO_0001134","EFO_0008585","MONDO_0100096","EFO_0003144","EFO_0000712","EFO_0008583","EFO_0000341","EFO_0004225","EFO_0008586"],"count":20},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications."}
{"id":"CHEMBL438303","canonicalSmiles":"N#Cc1cnn2c(Nc3ccccc3)nc(NCC3CCCCC3)nc12","inchiKey":"NCVMTHVSAJMOPI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL438303","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08353"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL445353","canonicalSmiles":"C=CCN(C)CCCCCCOc1ccc2c(-c3ccc(Br)cc3)coc2c1","inchiKey":"JYNZIOFUHBJABQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL445353","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02339"]},"childChemblIds":["CHEMBL114740"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL449317","canonicalSmiles":"COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O","inchiKey":"QUQPHWDTPGMPEX-QJBIFVCTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HESPERIDIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hesperidin","NSC-31048"],"crossReferences":{"PubChem":["144203999","50086731"],"Wikipedia":["Hesperidin"],"drugbank":["DB04703"],"chEBI":["28775"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL450","canonicalSmiles":"CCC1(CC)C(=O)NC(=O)N(C)C1=O","inchiKey":"FWJKNZONDWOGMI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHARBITAL","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Gemonil"],"synonyms":["Endiemal","Metharbital","Metharbital ciii","Metharbitone","NSC-27156"],"crossReferences":{"PubChem":["144206305"],"Wikipedia":["Metharbital"],"drugbank":["DB00463"]},"linkedTargets":{"rows":["ENSG00000145864","ENSG00000166206","ENSG00000163288"],"count":3},"linkedDiseases":{"rows":["EFO_0000474"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy."}
{"id":"CHEMBL4585668","canonicalSmiles":"CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F","inchiKey":"LOMMPXLFBTZENJ-ZACQAIPSSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"BELZUTIFAN","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Welireg"],"synonyms":["Belzutifan","MK-6482","MK6482","Mk-6482","PT-2977","PT2977","Pt 2977","Pt2977"],"linkedTargets":{"rows":["ENSG00000116016"],"count":1},"linkedDiseases":{"rows":["Orphanet_892","EFO_0000681","EFO_0000349","EFO_0001421","EFO_0003884","MONDO_0016748","EFO_1000045"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 5 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4594533","drugType":"Unknown","blackBoxWarning":false,"name":"CBX-129801","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CBX-129801","CBX129801","Cbx-129801","Cbx129801","Ersatta","Pegylated human c-peptide"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL464","canonicalSmiles":"CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C","inchiKey":"HQMNCQVAMBCHCO-DJRRULDNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETRETINATE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["France"," United States"],"classes":["Teratogenicity"],"year":1989},"tradeNames":["Tegison","Tigason"],"synonyms":["Acitretin related compound b","Etretinate","NSC-297936","RO 10-9359","RO-10-9359","RO-109359"],"crossReferences":{"PubChem":["144206054","170465372","50112753"],"Wikipedia":["Etretinate"],"chEBI":["4913"]},"linkedTargets":{"rows":["ENSG00000131759","ENSG00000077092","ENSG00000172819","ENSG00000204231","ENSG00000143171","ENSG00000186350"],"count":6},"linkedDiseases":{"rows":["EFO_0000676"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for psoriasis. It was withdrawn in France and  United States initially in 1989 due to Teratogenicity."}
{"id":"CHEMBL4650247","drugType":"Gene","blackBoxWarning":false,"name":"VERBRINACOGENE SETPARVOVEC","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FLT-180A","FLT180a","Verbrinacogene setparvovec"],"description":"Gene drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650326","canonicalSmiles":"C(=C/c1cccs1)\\c1cc[nH]n1","inchiKey":"FOHWAQGURRYJFK-ONEGZZNKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEREVALEFIM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ANG-3777","Ang-3777","Refanalin","SNV-003","Terevalefim"],"linkedTargets":{"rows":["ENSG00000105976"],"count":1},"linkedDiseases":{"rows":["HP_0001919"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4650339","canonicalSmiles":"O=C(CCC(=O)c1ccc2c(c1)OCCO2)c1ccccc1","inchiKey":"AOCDRSSVFUCURK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DALOSIRVAT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dalosirvat","SM-04554","SM04554","Sm04554"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4650437","drugType":"Antibody","blackBoxWarning":false,"name":"EBDAROKIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AK-101","AK101","Ak101","Ebdarokimab"],"linkedTargets":{"rows":["ENSG00000113302"],"count":1},"linkedDiseases":{"rows":["EFO_1001494","EFO_0000676"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL475398","canonicalSmiles":"Oc1ccc(-c2ccccc2)cc1O","inchiKey":"QDNPCYCBQFHNJC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-Phenylcatechol","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Phenylcatechol"],"crossReferences":{"drugbank":["DB07478"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4802194","drugType":"Unknown","blackBoxWarning":false,"name":"AZD-0284","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azd-0284","Azd0284"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL486954","canonicalSmiles":"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C","inchiKey":"XMRPGKVKISIQBV-XWOJZHJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL486954","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07557"],"chEBI":["30154"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL539770","canonicalSmiles":"CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl","inchiKey":"RNGHAJVBYQPLAZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TERODILINE HYDROCHLORIDE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL363295","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Germany"," Spain"," United Kingdom"],"classes":["Cardiotoxicity"],"year":1991},"tradeNames":["Micturin 12.5","Micturin 25"],"synonyms":["Terodiline hydrochloride"],"crossReferences":{"PubChem":["144206962"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in Germany,  Spain and  United Kingdom initially in 1991 due to Cardiotoxicity."}
{"id":"CHEMBL557","canonicalSmiles":"N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O","inchiKey":"AUYYCJSJGJYCDS-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DETROTHYRONINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DT-3","Detrothyronine","Dextrothyronine","NSC-46046","Rathyronine, (r)-"],"crossReferences":{"PubChem":["11112909"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL57242","canonicalSmiles":"CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(O)n2)cc1","inchiKey":"KGSXMPPBFPAXLY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZILSARTAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azilsartan","TAK-536"],"crossReferences":{"chEBI":["68850"]},"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["MONDO_0001134","EFO_0000400","MONDO_0005148","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL582857","canonicalSmiles":"COc1ccc(S(=O)(=O)N2C(=O)[C@@](c3ccccc3OC)(N3C[C@H](O)C[C@H]3C(=O)N(C)C)c3cc(Cl)ccc32)c(OC)c1","inchiKey":"NJXZWIIMWNEOGJ-WEWKHQNJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NELIVAPTAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nelivaptan","SR-149415","SSR-149,415","SSR-149415","SSR149415","Ssr149415"],"crossReferences":{"PubChem":["144210560"],"Wikipedia":["Nelivaptan"],"drugbank":["DB12643"]},"childChemblIds":["CHEMBL1098000"],"linkedTargets":{"rows":["ENSG00000198049"],"count":1},"linkedDiseases":{"rows":["MONDO_0002050","EFO_0005230"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL589586","canonicalSmiles":"COC(=O)/C=C/C(=O)O","inchiKey":"NKHAVTQWNUWKEO-NSCUHMNNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MONOMETHYL FUMARATE","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bafiertam"],"synonyms":["Fumaric acid monomethyl ester","Methyl Fumarate","Monomethyl fumarate","NSC-523835"],"crossReferences":{"drugbank":["DB14219"]},"linkedTargets":{"rows":["ENSG00000079999"],"count":1},"linkedDiseases":{"rows":["MONDO_0005301","EFO_0003929"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for multiple sclerosis and has 1 investigational indication."}
{"id":"CHEMBL603830","canonicalSmiles":"CCCOc1cc([C@]2(C)CNC(=O)O2)ccc1OC","inchiKey":"PCCPERGCFKIYIS-AWEZNQCLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DAXALIPRAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Daxalipram","[R]-Mesopram"],"crossReferences":{"drugbank":["DB01647"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL6640","canonicalSmiles":"NCCc1c[nH]c2ccccc12","inchiKey":"APJYDQYYACXCRM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRYPTAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11110664","124879002","14719299","90340989"],"Wikipedia":["Tryptamine"],"drugbank":["DB08653"],"chEBI":["16765"]},"childChemblIds":["CHEMBL1255796"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL702","canonicalSmiles":"CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O","inchiKey":"IVBHGBMCVLDMKU-GXNBUGAJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIPERACILLIN","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Piperacillin","Piperacillin hydrate","Piperacillin monohydrate"],"crossReferences":{"DailyMed":["piperacillin%20sodium"],"Wikipedia":["Piperacillin"],"drugbank":["DB00319"],"chEBI":["8232"]},"childChemblIds":["CHEMBL1200820"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 8 approved and 18 investigational indications."}
{"id":"CHEMBL71752","canonicalSmiles":"CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32","inchiKey":"DDNCQMVWWZOMLN-IRLDBZIGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VINPOCETINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cavinton"],"synonyms":["AY-27,255","AY-27255","Apovincaminic acid ethyl ester","Bravinton","Ceractin","Ethyl apovincamin-22-oate","NSC-760093","Rgh 4405","Tcv 3b","Ultra-vinca","Vinpocetine","Vinporal"],"crossReferences":{"PubChem":["104171371","144204199","144204390","170465859","50103960","50103961","56424092","85231349","855619","90341018"],"Wikipedia":["Vinpocetine"],"drugbank":["DB12131"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for attention deficit hyperactivity disorder and has 1 investigational indication."}
{"id":"CHEMBL7413","canonicalSmiles":"C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O","inchiKey":"NZXKDOXHBHYTKP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"METHOHEXITAL","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Methohexital","Methohexital civ","Methohexitone"],"crossReferences":{"DailyMed":["methohexital%20sodium"],"Wikipedia":["Methohexital"],"drugbank":["DB00474"],"chEBI":["102216"]},"childChemblIds":["CHEMBL30219"],"linkedTargets":{"rows":["ENSG00000145864","ENSG00000166206","ENSG00000163288"],"count":3},"linkedDiseases":{"rows":["EFO_0000289","MONDO_0002050","EFO_0003761"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA."}
{"id":"CHEMBL750","canonicalSmiles":"N=S(=O)(O)Cc1noc2ccccc12","inchiKey":"UBQNRHZMVUUOMG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZONISAMIDE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Zonegran","Zonisamide"],"synonyms":["AD-810","CI-912","Excegran","N03AX15","PD-110843","Zonisamide"],"crossReferences":{"DailyMed":["zonisamide"],"PubChem":["144205122","49666067","90341782"],"Wikipedia":["Zonisamide"],"drugbank":["DB00909"],"chEBI":["10127"]},"childChemblIds":["CHEMBL1514931","CHEMBL1596271"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000196876","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000153253"],"count":10},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0004566","EFO_0005203","EFO_0004319","EFO_0002610","EFO_1000877","EFO_0003768","HP_0001250","EFO_0001073","MONDO_0002046","MONDO_0005277","EFO_0000474","EFO_0000289","EFO_1001254","Orphanet_36899","HP_0001300","MONDO_0005180","EFO_0004238","MONDO_0007079","EFO_0003108","EFO_0005411"],"count":21},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for epilepsy and seizure and has 16 investigational indications."}
{"id":"CHEMBL752","canonicalSmiles":"Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"UDMBCSSLTHHNCD-KQYNXXCUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ADENOSINE PHOSPHATE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Adenyl","My-b-den"],"synonyms":["5'-adenylic acid","A 5MP","A-5MP","Adenosine Monophosphate","Adenosine phosphate","NSC-20264","Vitamin b8"],"crossReferences":{"PubChem":["144205599","170466132","26756674"],"Wikipedia":["Adenosine_monophosphate"],"drugbank":["DB00131"],"chEBI":["16027"]},"childChemblIds":["CHEMBL1627080","CHEMBL1315633"],"description":"Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication. It was withdrawn in United States."}
{"id":"CHEMBL8809","canonicalSmiles":"CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC","inchiKey":"WAOQONBSWFLFPE-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RACLOPRIDE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Raclopride"],"crossReferences":{"PubChem":["11114224","144204512","170466218","26719717","26752250","90340860"],"Wikipedia":["Raclopride"],"drugbank":["DB12518"]},"childChemblIds":["CHEMBL1369632","CHEMBL2104769"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL917","canonicalSmiles":"O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F","inchiKey":"ODKNJVUHOIMIIZ-RRKCRQDMSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLOXURIDINE","yearOfFirstApproval":1970,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["F.u.d.r.","Floxuridine","Fudr"],"synonyms":["5-Fluoro-2-deoxyuridine","5-fudr","FUDR","Floxuridine","Fluoruridine deoxyribose","NSC-27640"],"crossReferences":{"DailyMed":["floxuridine"],"PubChem":["124886843","144204443","170465247","29215018","29215019","50104188","855946","93576919"],"Wikipedia":["Floxuridine"],"drugbank":["DB00322"],"chEBI":["60761"]},"linkedTargets":{"rows":["ENSG00000176890"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000365","EFO_0000503","MONDO_0015686","MONDO_0008170","MONDO_0000956","Orphanet_44890","EFO_1000657","MONDO_0007576","MONDO_0021063","MONDO_0002087","EFO_0004243","EFO_0005221","EFO_1001951","EFO_0000311","EFO_1001961","MONDO_0002691","MONDO_0001056","EFO_1001480","MONDO_0002158","EFO_0000182","EFO_0004142","MONDO_0024880"],"count":23},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for cancer and neoplasm and has 17 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL981","canonicalSmiles":"CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O","inchiKey":"MQOBSOSZFYZQOK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENOFIBRIC ACID","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fenocor-67","Fenogal","Fibricor","Lipanthyl","Lipofen","Lofibra","Supralip","Trilipix"],"synonyms":["Fenofibrate free acid","Fenofibrate related compound b","Fenofibric acid","LF-153","NSC-281318","Procetofenic acid"],"crossReferences":{"DailyMed":["choline%20fenofibrate","fenofibric%20acid"],"drugbank":["DB13873"],"chEBI":["83469"]},"childChemblIds":["CHEMBL1201745"],"linkedTargets":{"rows":["ENSG00000186951"],"count":1},"linkedDiseases":{"rows":["EFO_0004211","HP_0003124","MONDO_0100096","MONDO_0001751","EFO_0001645","Orphanet_79211","EFO_0002939","EFO_0000319","MONDO_0007079","EFO_0009321","MONDO_0005148","Orphanet_309005"],"count":12},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 8 investigational indications."}
